STOCK TITAN

[6-K] Haleon plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Haleon has announced a significant share buyback transaction as part of its program announced on March 28, 2025. On June 20, 2025, the company purchased 1,016,186 ordinary shares for cancellation at prices ranging from 382.70p to 388.00p per share, with a volume-weighted average price of 385.10p.

Following the settlement, Haleon's registered share capital consists of 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,987,477,204.

Haleon, a global consumer health leader listed on LSE/NYSE, maintains a portfolio across six major categories:

  • Oral Health
  • Vitamins, Minerals and Supplements (VMS)
  • Pain Relief
  • Respiratory Health
  • Digestive Health
  • Therapeutic Skin Health

The company's brand portfolio includes notable names such as Advil, Centrum, Sensodyne, and Voltaren.

Haleon ha annunciato una significativa operazione di riacquisto di azioni nell'ambito del programma comunicato il 28 marzo 2025. Il 20 giugno 2025, la società ha acquistato 1.016.186 azioni ordinarie da annullare, a prezzi compresi tra 382,70p e 388,00p per azione, con un prezzo medio ponderato per volume di 385,10p.

Dopo il regolamento, il capitale sociale registrato di Haleon è composto da 8.991.557.409 azioni ordinarie del valore nominale di £0,01 ciascuna, di cui 4.080.205 detenute come azioni proprie. Il numero totale di diritti di voto è ora pari a 8.987.477.204.

Haleon, leader globale nel settore della salute dei consumatori quotato alla LSE/NYSE, gestisce un portafoglio in sei categorie principali:

  • Salute Orale
  • Vitamine, Minerali e Integratori (VMS)
  • Antidolorifici
  • Salute Respiratoria
  • Salute Digestiva
  • Salute Terapeutica della Pelle

Il portafoglio di marchi dell’azienda include nomi importanti come Advil, Centrum, Sensodyne e Voltaren.

Haleon ha anunciado una importante operación de recompra de acciones como parte de su programa anunciado el 28 de marzo de 2025. El 20 de junio de 2025, la compañía adquirió 1.016.186 acciones ordinarias para cancelarlas, a precios que oscilaron entre 382,70p y 388,00p por acción, con un precio medio ponderado por volumen de 385,10p.

Tras la liquidación, el capital social registrado de Haleon consta de 8.991.557.409 acciones ordinarias de £0,01 cada una, con 4.080.205 mantenidas como acciones en tesorería. El número total de derechos de voto es ahora 8.987.477.204.

Haleon, líder global en salud del consumidor cotizado en LSE/NYSE, mantiene un portafolio en seis categorías principales:

  • Salud Oral
  • Vitaminas, Minerales y Suplementos (VMS)
  • Alivio del Dolor
  • Salud Respiratoria
  • Salud Digestiva
  • Salud Terapéutica de la Piel

El portafolio de marcas de la compañía incluye nombres destacados como Advil, Centrum, Sensodyne y Voltaren.

Haleon은 2025년 3월 28일 발표한 프로그램의 일환으로 대규모 자사주 매입 거래를 발표했습니다. 2025년 6월 20일, 회사는 1,016,186주의 보통주를 취소 목적으로 주당 382.70펜스에서 388.00펜스 사이의 가격으로 매입했으며, 거래량 가중 평균 가격은 385.10펜스였습니다.

결제 후 Haleon의 등록 자본금은 액면가 £0.01인 8,991,557,409주의 보통주로 구성되며, 그중 4,080,205주는 자사주로 보유하고 있습니다. 현재 총 의결권 수는 8,987,477,204입니다.

런던 증권거래소(LSE)와 뉴욕 증권거래소(NYSE)에 상장된 글로벌 소비자 건강 선도 기업인 Haleon은 여섯 가지 주요 카테고리에서 포트폴리오를 운영하고 있습니다:

  • 구강 건강
  • 비타민, 미네랄 및 보충제(VMS)
  • 통증 완화
  • 호흡기 건강
  • 소화기 건강
  • 치료용 피부 건강

회사의 브랜드 포트폴리오에는 Advil, Centrum, Sensodyne, Voltaren과 같은 유명 브랜드가 포함되어 있습니다.

Haleon a annoncé une opération importante de rachat d’actions dans le cadre de son programme annoncé le 28 mars 2025. Le 20 juin 2025, la société a acquis 1 016 186 actions ordinaires en vue de leur annulation, à des prix allant de 382,70p à 388,00p par action, avec un prix moyen pondéré par volume de 385,10p.

Après le règlement, le capital social enregistré de Haleon se compose de 8 991 557 409 actions ordinaires d’une valeur nominale de £0,01 chacune, dont 4 080 205 sont détenues en actions propres. Le nombre total de droits de vote est désormais de 8 987 477 204.

Haleon, leader mondial de la santé grand public coté à la LSE/NYSE, maintient un portefeuille réparti dans six grandes catégories :

  • Santé bucco-dentaire
  • Vitamines, minéraux et compléments (VMS)
  • Soulagement de la douleur
  • Santé respiratoire
  • Santé digestive
  • Santé thérapeutique de la peau

Le portefeuille de marques de l’entreprise comprend des noms renommés tels qu’Advil, Centrum, Sensodyne et Voltaren.

Haleon hat eine bedeutende Aktienrückkauftransaktion im Rahmen seines am 28. März 2025 angekündigten Programms bekanntgegeben. Am 20. Juni 2025 erwarb das Unternehmen 1.016.186 Stammaktien zur Vernichtung zu Preisen zwischen 382,70p und 388,00p pro Aktie, mit einem volumenbasierten Durchschnittspreis von 385,10p.

Nach der Abwicklung besteht das eingetragene Grundkapital von Haleon aus 8.991.557.409 Stammaktien mit einem Nennwert von je £0,01, von denen 4.080.205 als eigene Aktien gehalten werden. Die Gesamtzahl der Stimmrechte beträgt nun 8.987.477.204.

Haleon, ein weltweit führendes Unternehmen im Bereich der Gesundheitsprodukte für Verbraucher, das an der LSE/NYSE notiert ist, verfügt über ein Portfolio in sechs Hauptkategorien:

  • Mundgesundheit
  • Vitamine, Mineralien und Nahrungsergänzungsmittel (VMS)
  • Schmerzlinderung
  • Atemwegsgesundheit
  • Verdauungsgesundheit
  • Therapeutische Hautpflege

Das Markenportfolio des Unternehmens umfasst bekannte Namen wie Advil, Centrum, Sensodyne und Voltaren.

Positive
  • Haleon executed a share buyback of 1,016,186 shares at an average price of 385.10p, demonstrating confidence in company valuation and commitment to returning capital to shareholders
Negative
  • None.

Haleon ha annunciato una significativa operazione di riacquisto di azioni nell'ambito del programma comunicato il 28 marzo 2025. Il 20 giugno 2025, la società ha acquistato 1.016.186 azioni ordinarie da annullare, a prezzi compresi tra 382,70p e 388,00p per azione, con un prezzo medio ponderato per volume di 385,10p.

Dopo il regolamento, il capitale sociale registrato di Haleon è composto da 8.991.557.409 azioni ordinarie del valore nominale di £0,01 ciascuna, di cui 4.080.205 detenute come azioni proprie. Il numero totale di diritti di voto è ora pari a 8.987.477.204.

Haleon, leader globale nel settore della salute dei consumatori quotato alla LSE/NYSE, gestisce un portafoglio in sei categorie principali:

  • Salute Orale
  • Vitamine, Minerali e Integratori (VMS)
  • Antidolorifici
  • Salute Respiratoria
  • Salute Digestiva
  • Salute Terapeutica della Pelle

Il portafoglio di marchi dell’azienda include nomi importanti come Advil, Centrum, Sensodyne e Voltaren.

Haleon ha anunciado una importante operación de recompra de acciones como parte de su programa anunciado el 28 de marzo de 2025. El 20 de junio de 2025, la compañía adquirió 1.016.186 acciones ordinarias para cancelarlas, a precios que oscilaron entre 382,70p y 388,00p por acción, con un precio medio ponderado por volumen de 385,10p.

Tras la liquidación, el capital social registrado de Haleon consta de 8.991.557.409 acciones ordinarias de £0,01 cada una, con 4.080.205 mantenidas como acciones en tesorería. El número total de derechos de voto es ahora 8.987.477.204.

Haleon, líder global en salud del consumidor cotizado en LSE/NYSE, mantiene un portafolio en seis categorías principales:

  • Salud Oral
  • Vitaminas, Minerales y Suplementos (VMS)
  • Alivio del Dolor
  • Salud Respiratoria
  • Salud Digestiva
  • Salud Terapéutica de la Piel

El portafolio de marcas de la compañía incluye nombres destacados como Advil, Centrum, Sensodyne y Voltaren.

Haleon은 2025년 3월 28일 발표한 프로그램의 일환으로 대규모 자사주 매입 거래를 발표했습니다. 2025년 6월 20일, 회사는 1,016,186주의 보통주를 취소 목적으로 주당 382.70펜스에서 388.00펜스 사이의 가격으로 매입했으며, 거래량 가중 평균 가격은 385.10펜스였습니다.

결제 후 Haleon의 등록 자본금은 액면가 £0.01인 8,991,557,409주의 보통주로 구성되며, 그중 4,080,205주는 자사주로 보유하고 있습니다. 현재 총 의결권 수는 8,987,477,204입니다.

런던 증권거래소(LSE)와 뉴욕 증권거래소(NYSE)에 상장된 글로벌 소비자 건강 선도 기업인 Haleon은 여섯 가지 주요 카테고리에서 포트폴리오를 운영하고 있습니다:

  • 구강 건강
  • 비타민, 미네랄 및 보충제(VMS)
  • 통증 완화
  • 호흡기 건강
  • 소화기 건강
  • 치료용 피부 건강

회사의 브랜드 포트폴리오에는 Advil, Centrum, Sensodyne, Voltaren과 같은 유명 브랜드가 포함되어 있습니다.

Haleon a annoncé une opération importante de rachat d’actions dans le cadre de son programme annoncé le 28 mars 2025. Le 20 juin 2025, la société a acquis 1 016 186 actions ordinaires en vue de leur annulation, à des prix allant de 382,70p à 388,00p par action, avec un prix moyen pondéré par volume de 385,10p.

Après le règlement, le capital social enregistré de Haleon se compose de 8 991 557 409 actions ordinaires d’une valeur nominale de £0,01 chacune, dont 4 080 205 sont détenues en actions propres. Le nombre total de droits de vote est désormais de 8 987 477 204.

Haleon, leader mondial de la santé grand public coté à la LSE/NYSE, maintient un portefeuille réparti dans six grandes catégories :

  • Santé bucco-dentaire
  • Vitamines, minéraux et compléments (VMS)
  • Soulagement de la douleur
  • Santé respiratoire
  • Santé digestive
  • Santé thérapeutique de la peau

Le portefeuille de marques de l’entreprise comprend des noms renommés tels qu’Advil, Centrum, Sensodyne et Voltaren.

Haleon hat eine bedeutende Aktienrückkauftransaktion im Rahmen seines am 28. März 2025 angekündigten Programms bekanntgegeben. Am 20. Juni 2025 erwarb das Unternehmen 1.016.186 Stammaktien zur Vernichtung zu Preisen zwischen 382,70p und 388,00p pro Aktie, mit einem volumenbasierten Durchschnittspreis von 385,10p.

Nach der Abwicklung besteht das eingetragene Grundkapital von Haleon aus 8.991.557.409 Stammaktien mit einem Nennwert von je £0,01, von denen 4.080.205 als eigene Aktien gehalten werden. Die Gesamtzahl der Stimmrechte beträgt nun 8.987.477.204.

Haleon, ein weltweit führendes Unternehmen im Bereich der Gesundheitsprodukte für Verbraucher, das an der LSE/NYSE notiert ist, verfügt über ein Portfolio in sechs Hauptkategorien:

  • Mundgesundheit
  • Vitamine, Mineralien und Nahrungsergänzungsmittel (VMS)
  • Schmerzlinderung
  • Atemwegsgesundheit
  • Verdauungsgesundheit
  • Therapeutische Hautpflege

Das Markenportfolio des Unternehmens umfasst bekannte Namen wie Advil, Centrum, Sensodyne und Voltaren.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of June 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
23 June 2025 - “Transaction in Own Shares”
 
 
99.1
 
 
 
 
Haleon plc: Transaction in own shares
 
23 June 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 28 March 2025 (the "Buyback Programme").
 
Date of purchase:
20 June 2025
Number of Shares purchased:
1,016,186
Highest price paid per share (p):
388.00
Lowest price paid per share (p):
382.70
Volume weighted average price paid per share (p):
385.10

Following the settlement of the above, the Company's registered share capital is 8,991,557,409 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,987,477,204 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK(the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/8575N_1-2025-6-20.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 

Enquiries
 
Investors
 
Media
 
Jo Russell
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel
+44 7552 484646
Victoria Durman
+44 7894 505730
Emma White
+44 7823 523562
 
 
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com.
 
 
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: June 23, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary
 

FAQ

How many shares did HLN buy back on June 20, 2025?

Haleon (HLN) purchased 1,016,186 shares on June 20, 2025, as part of its share buyback programme announced on March 28, 2025. The volume weighted average price paid per share was 385.10 pence.

What is HLN's total number of voting shares after the June 2025 buyback?

After the share buyback settlement, Haleon has 8,987,477,204 ordinary shares with voting rights. The company's total registered share capital is 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 shares held as treasury shares.

What was the price range for HLN's share buyback on June 20, 2025?

During the June 20, 2025 buyback, Haleon paid between 382.70 pence (lowest price) and 388.00 pence (highest price) per share, with a volume weighted average price of 385.10 pence per share.

When did HLN announce its current share buyback program?

Haleon announced its current share buyback programme on March 28, 2025. This program is currently ongoing with the latest reported purchase occurring on June 20, 2025.

What are HLN's major product categories as of 2025?

Haleon's product portfolio spans six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

47.15B
4.49B
0.02%
11.99%
0.59%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge